tiprankstipranks
Syndax reports new data from AUGMENT-102 trial
PremiumThe FlySyndax reports new data from AUGMENT-102 trial
1M ago
Syndax reports new data from BEAT AML trial of revumenib/venetoclax/azacitidine
PremiumThe Fly
Syndax reports new data from BEAT AML trial of revumenib/venetoclax/azacitidine
1M ago
Pyxis Oncology appoints Metzger to board of directors
PremiumThe Fly
Pyxis Oncology appoints Metzger to board of directors
1M ago
Syndax reports Q1 EPS (85c), consensus (98c)
PremiumThe FlySyndax reports Q1 EPS (85c), consensus (98c)
2M ago
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
PremiumPress Releases
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
2M ago
Syndax price target lowered to $32 from $35 at Citi
PremiumThe Fly
Syndax price target lowered to $32 from $35 at Citi
3M ago
Syndax management to meet with BTIG
PremiumThe FlySyndax management to meet with BTIG
4M ago
Syndax completes enrollment in AUGMENT-101 trial
PremiumThe Fly
Syndax completes enrollment in AUGMENT-101 trial
4M ago
Syndax granted Priority Review for NDA for revumenib by FDA
PremiumThe Fly
Syndax granted Priority Review for NDA for revumenib by FDA
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100